News – Page 1122 – Endpoints News

Scott Gottlieb gave a savvy review of what we can expect at the FDA; When times got rough, a biotech CEO demonstrated ...

9 years ago

Candid Truths From A Biotech IPO

9 years ago

Novartis finds its next mass-market ophthalmology drug candidate at a small virtual biotech with a global view

9 years ago

Adaptimmune raises $106M for pipeline work; KaloBios chief says biotech is on track for Chagas drug filing

9 years ago

Study highlights the FDA’s speed in approving cancer drugs as a new commish looks to rev up reviews

9 years ago

The stellar antibody shop at Regeneron wins a ‘breakthrough’ tag for its next big PhIII drug

9 years ago

Spark carefully records a safe step forward for closely-watched hemophilia gene therapy

9 years ago

Zavante hits the finish line, declaring a pivotal win for its antibiotic now headed (eventually) to the FDA

9 years ago

Allergan’s Botox misses the bullseye in PhII depression study, but researchers confident they can hit it in a major ...

9 years ago

Much criticized Mallinckrodt bows out of PhRMA ahead of some tightened restrictions on membership

9 years ago

Thiel-backed Azitra raises $3M for skin microbiome R&D; Crushed by clinical failure, Aviragen launches strategic ...

9 years ago

With a competitive Bill Sibold taking the helm at Sanofi Genzyme, longtime exec David Meeker makes an exit

9 years ago

Stepping out as a global player, a restructured Takeda enrolls 20,000-plus in new dengue PhIII in a showdown with ...

9 years ago

Scott Gottlieb aced his confirmation hearing, vowing to maintain R&D gold standard

9 years ago

Takeda partners with an upstart drugs-from-bugs microbiome player inspired by a fecal transplantation biz

9 years ago

Acorda is shifting into survival mode. And it’s going to start by axing more than 100 staffers.

9 years ago

Allergan vet takes the CEO’s job at Third Rock’s Relay; Verona Pharma files $86M IPO

9 years ago

Bristol-Myers joins the IDO rush with its own in-house combo program for Opdivo

9 years ago

Small biotech — big ambitions. Viralytics’ oncolytics therapy makes the showcase round at #AACR17 with positive ...

9 years ago

NewLink grabs the AACR spotlight with IDO pathway, Keytruda combo -- shares blitzed

9 years ago

Bristol-Myers’ checkpoint star Opdivo fails a PhIII study for glioblastoma

9 years ago

In a first for deuterated drugs, FDA (finally) OKs Teva’s would-be Huntington’s blockbuster Austedo

9 years ago

Paratek shares shoot up on a positive PhIII and a slow-mo shot at FDA/EMA OK for its antibiotic

9 years ago

Roche scores a success for Alecensa PhIII; FDA schedules AdComm for Heplisav-B; New CMO at Sarepta

9 years ago

First page Previous page 1119 1120 112111221123 1124 1125 Next page Last page